Ethiopian Pharmaceutical Manufacturing Sh. Co.

epharmsc.com

The Ethiopian Pharmaceuticals Manufacturing Sh. Co. (EPHARM) is a pioneer in the pharmaceutical manufacturing industry of Ethiopia. It is now 52 years old. It had been the only pharmaceutical manufacturer for more than 36 years in the country. It’s headquarter is located in Nifas Silk Lafto subcity, Addis Ababa. EPHARM is currently producing different dosage forms, which makes it peculiar from many of the local pharmaceutical manufacturers. EPHARM has been producing high quality and affordable medicine that have addressed the critical health problems of the Ethiopian people for more than fifty years. The products encompass; Antibiotics, Infusions, Topical drugs, Drugs that act on central nervous system (CNS), Gastroenterological drugs, Vitamins, Anti-Allergic, Analgesics, Anti- Tussives and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

M-PHARMA AND KYOWA KIRIN SIGN EXCLUSIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF ILOFOTASE ALFA IN JAPAN

AM-Pharma | September 08, 2021

news image

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd, a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase. ...

Read More

PHARMACY MARKET

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals | November 20, 2021

news image

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More

BUSINESS INSIGHTS

TRIASTEK AND SIEMENS ANNOUNCED A STRATEGIC PARTNERSHIP TO ADVANCE THE PHARMACEUTICAL INDUSTRY'S DIGITAL TRANSFORMATION

Triastek, Inc | March 21, 2022

news image

Triastek, Inc. and Siemens Ltd., China, have agreed to collaborate on digital technologies for the worldwide pharmaceutical business. Triastek's industry-leading 3D printing and digital pharmaceutical technologies, combined with Siemens' worldwide experience in automation and digitalization, should result in unique and disruptive pharmaceutical research and production solutions. Pharmaceutical companies have been encouraged to modernize their manufacturing processes by ado...

Read More

BEIGENE REPORTS POSITIVE PHASE III INTERIM ANALYSIS FOR LUNG CANCER DRUG

MedCity News | April 14, 2020

news image

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with ...

Read More
news image

PHARMACY MARKET

M-PHARMA AND KYOWA KIRIN SIGN EXCLUSIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF ILOFOTASE ALFA IN JAPAN

AM-Pharma | September 08, 2021

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd, a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase. ...

Read More
news image

PHARMACY MARKET

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals | November 20, 2021

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More
news image

BUSINESS INSIGHTS

TRIASTEK AND SIEMENS ANNOUNCED A STRATEGIC PARTNERSHIP TO ADVANCE THE PHARMACEUTICAL INDUSTRY'S DIGITAL TRANSFORMATION

Triastek, Inc | March 21, 2022

Triastek, Inc. and Siemens Ltd., China, have agreed to collaborate on digital technologies for the worldwide pharmaceutical business. Triastek's industry-leading 3D printing and digital pharmaceutical technologies, combined with Siemens' worldwide experience in automation and digitalization, should result in unique and disruptive pharmaceutical research and production solutions. Pharmaceutical companies have been encouraged to modernize their manufacturing processes by ado...

Read More
news image

BEIGENE REPORTS POSITIVE PHASE III INTERIM ANALYSIS FOR LUNG CANCER DRUG

MedCity News | April 14, 2020

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with ...

Read More